Armune BioScience Wins Best Poster of the AUA Moderated Poster Session at AUA 2017 in Boston, MA
Armune BioScience attended the 2017 American Urological Association (AUA) Annual Meeting in Boston on May 12–16.
Armune’s poster, A Novel Serum Based Multiplexed 21 Autoantibody Assay to Predict High-grade Prostate Cancer at Initial Biopsy, received positive and meaningful feedback from attendees and ultimately won Best Poster of the Moderated Poster Session in the biomarkers category.
Armune BioScience is honored by this achievement and was thrilled to have had numerous engaging conversations regarding APIFINY and the role it plays in prostate cancer risk assessment.
APIFINY is the only cancer specific, non-PSA blood test available today. The simple blood test measures unique biological markers known to be associated with an immune system response to prostate cancer.
Thank you to the AUA for the award and a successful conference.